GSK and J&J alum Vi­jay Red­dy to take con­trol of R&D at Tmu­ni­ty; An­drew Hirsch ex­its Agios for CEO job at C4 Ther­a­peu­tics

Vi­jay Red­dy was seek­ing a re­turn to the US when he left his role as CMO at Lon­don-based Au­to­lus this sum­mer. Philadel­phia is that land­ing spot, as the T cell im­munother­a­py play­er Tmu­ni­ty has put him in charge of R&D.

Red­dy ar­rives at the Penn spin­out with plen­ty of Big Phar­ma bona fides af­ter de­vel­op­ing the CAR-T cell clin­i­cal pro­gram at Au­to­lus. Tmu­ni­ty’s new chief R&D of­fi­cer was a se­nior di­rec­tor and led ear­ly clin­i­cal de­vel­op­ment at J&J sub­sidiary Janssen from 2013-16, and from 2009-13, he was GSK’s med­ical di­rec­tor, can­cer re­search and clin­i­cal de­vel­op­ment.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.